



Produktinformation / NanoSticka

NanoSticka er Ferle Produkter AB's eget produkt, som både er produkt- og kvalitetssikret. Selve fremstillingen, er lagt ud til underleverandør i USA. Producenten har den amerikanske FDA (Food and Drug Administration) godkendelse, samt CE-mærkning for hele Europa. Ligeledes foretager Ferle produkter selv stikprøvevis kvalitetskontrol.

Laboratoriet på Uddevalla sygehus (akkrediteret lab.) har i forbindelse med Westma's (Offentlig indkøbsafdeling i Göteborg-området) licitation, lavet en afprøvning af NanoSticka.

Ligeledes er der lavet flere interne afprøvninger i forbindelse med øvrige licitationer.

Vor brede internationale kontakflade, gør det muligt at få fremstillet reagenser som efterspørgeres på det nordiske marked. (eksempelvis Buprenorphine, THC 200 ng/ml og nu Tramadol m.fl.) Samling og produktion forgår hos underleverandør i USA.

Krydsreaktionsliste er udarbejdet af underleverandør, på baggrund af reagensers sammensætning samt relevant litteratur (se bagside). Opdateres jævnligt.

Detektionstiderne har følgende kilder: Vejledninger fra leverandør, amerikansk litteratur, Roche's: 'Drugs of abuse – Pharmacology and detection' (1992), studier af blandt andet; chefkemist fra Uddevalla sygehus, microbiolog fra Universitetssygehuset i Lund, samt erfaringer og studier fra stor kundegruppe. Dynamisk, justeres ind efter udvikling af de enkelte præparaters konc., renhed mm.

**NanoSticka****INTENDED USE**

The RAPID DRUG SCREEN INDIVIDUAL is lateral flow, one-step immunoassay for the qualitative detection of THC, OPI, AMP, M-AMP, BZO, COC, PCP, BAR, MTD, BUP at the following cut-off concentrations.

THC	11-nor- Δ^9 -THC-9-COOH	50 ng/ml
OPI	Morphine	300 ng/ml
AMP	Amphetamine	300 ng/ml
M-AMP	Methamphetamine	500 ng/ml
BZO	Benzodiazepine	300 ng/ml
COC	Benzoyllecgonine	300 ng/ml
PCP	(Angeldust)	25 ng/ml
BAR	Barbiturater	300 ng/ml
MTD	Methadone	300 ng/ml
BUP	Buprenorphine / subutex	10 ng/ml

The following structurally related compounds produce positive results when tested at levels equal to or greater than the concentrations listed below:

Compound	Concentration (ng/ml)
----------	-----------------------

Amphetamine	
d-Amphetamine	300
l-Amphetamine	10,000
(+/-)3,4-methylenedioxyamphetamine (MDMA)	5,000

Methamphetamine	
d-methamphetamine	500
D-Amphetamine	50,000
Chloroquine	50,000
(+/-)-Ephedrine	50,000
l-Methamphetamine(l-deoxyephedrine)	25,000
(+/-)3,4-methylenedioxy-methamphetamine (MDMA)	2,000
Procaine	10,000
-Phenylethylamine	50,000
Ranitidine	50,000

Benzodiazepine	
Oxazepam	300
Alprazolam	150
Bromazepam	800
Chlordiazepoxide	300
Clobazam	200
Clonazepam	25,000
Clorazepam	100
Delorazepam	6,000
Diazepam	150
Estazolam	300
Flunitrazepam	1,000
Flurazepam	300
Lorazepam	1,500
Lormetazepam	1,000
Medazepam	2,000
Nitrazepam	1,000
Nordiazepam	100
Przepam	1,000
Temazepam	150
Triazolam	1,500

THC	
11-nor-D9-THC-9-COOH	50
11-nor-D8-THC-9-COOH	50
11-hydroxy- Δ^9 -Tetrahydrocannabinol	2,500
8-Tetrahydrocannabinol	7,500
9-Tetrahydrocannabinol	10,000
Cannabinol	10,000
Cannabidiol	1000,000

PCP	
Phencyclidine	25
Thienylecyclohexylpiperidine (TCP)	2500

Compound	Concentration (ng/ml)
----------	-----------------------

Cocaine	
Benzoylecgonine	300
Cocaine	300

Morphine	
Morphine	300
Codeine	300
Ethyl morphine	300
Hydrocodone	375
Hydromorphone	400
Meperidine	30,000
Morphine-3-glucuronide	490
Norcodeine	30,000
Oxycodone	15,000
Thebaine	30,000

Methadone	
Diphenhydramine	100,000
Doxylamine	>100,000
EDDP	>100,000
EMDP	>100,000
Imipramine	>100,000
LAAM	2,000
Meperidine	>100,000
Methadone	300
Nor-LAAM	10,000

Buprenorphine	
Buprenorphine-3- β -d-glucuronide	10
Buprenorphine	200

Barbiturate	
Allobarbitol	500
Alphenal	400
Amobarbital	2,000
Aprobarbital	200
Barbital	1,500
Butalbital	200
Cyclopentobarbital	500
Pentobarbital	1,000
Phenobarbital	3,000
Phenytoin	5,000
Secobarbital	300
Thiopental	>100,000

The following compounds were found **not** to cross-react when tested at concentrations up to 100 ug/ml:

Acetone	Hemoglobin
Acetaminophen	Imipramine
Albumin	(+/-)-Isoproterenol
Amitriptyline	Lidocaine
Ampicillin	(1R, 2S)-(-)-N-Methyl-Ephedrine
Aspartame	Naloxone
Aspirin	Naltrexone
Atropine	Naphthalena Acetic Acid
Benzocaine	(+)-Naproxen
Bilirubin	(+/-)-Norephedrine
Caffeine	Oxalic Acid
(+)-Chlorpheniramine	Penicillin-G
(+/-)-Chlorpheniramine	Pheniramine
Creatine	Phenothiazine
Dextrometorphan	Quinidine
4-Dimethylaminoantipyrine	Sodium Chloride
Dopamine	Sulindac
(+)-Ephedrine	Thioridazine
(-)-Ephedrine	Trimethobenzamide
(+)-Epinephrine	Tyramine
Erythromycin	Vitamin C
Ethanol	Trifluoperazine
Furosemide	
Glucose	
Guaiacol Glyceryl Ether	

References

- Hawks RL, Chiang CN, eds. *Urine Testing for Drugs of Abuse*. Rockville, MD: National Institute on Drug Abuse (NIDA), Research Monograph 73;1986.
- Baselt RC. *Disposition of Toxic Drugs and Chemicals in Man*. 2nd Ed., Davis, CA: Biomedical Publ.;1982;p.488
- Fed. Register, Departement of Health and Human Services, mandatory Guidelines for Federal workplace Drug Testing Programs, 53,69.
- McBay, A.J., Clin. Chem. 33, 33B - 40B, 1987.
- Gilman, AG., and Goodman, L.S., *The Pharmacological al Basis of Therapeutics*, eds, Mac Mac Millan Publishing, New York, NY, 1980.